Archives of Disease in Childhood - Fetal and Neonatal Edition 2008;93:F442-F447
ORIGINAL ARTICLES
Antenatal glucocorticoid treatment is not associated with long-term metabolic risks in individuals born before 32 weeks of gestation
1 Department of Pediatrics, Leiden University Medical Center, the Netherlands
2 Department of Clinical Epidemiology, Leiden University Medical Center, the Netherlands
3 Department of Pediatric Nephrology, Erasmus MC-Sophia Children’s Hospital, University Medical Center Rotterdam, the Netherlands
4 Department of Clinical Chemistry, Leiden University Medical Center, the Netherlands
5 Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, the Netherlands
Correspondence to:
Martijn J J Finken, Department of Pediatrics, Leiden University Medical Center, P. O. Box 9600, 2300 RC Leiden, The Netherlands; m.j.j.finken{at}lumc.nl
Background: A single course of maternal glucocorticoid treatment is effective in reducing neonatal mortality after preterm birth. However, in animals, maternal glucocorticoid treatment is associated with lifelong hyperglycaemia and hypertension, and impaired nephrogenesis in offspring. Findings from studies in humans on this topic are highly contradictory due to a number of methodological flaws, and renal function after glucocorticoid exposure has never been assessed.
Objectives: To assess in individuals born <32 gestational weeks whether antenatal glucocorticoid treatment for preterm birth is associated with long-term metabolical risks, including renal function, in adulthood.
Design: Birth cohort study.
Setting: Multicentre study.
Patients: 412 19 year olds born <32 gestational weeks from the Project On Preterm and Small-for-gestational-age infants (POPS) cohort.
Interventions: Maternal betamethasone 12 mg administered twice with a 24 h interval.
Main outcome measures: Body composition, insulin resistance, the serum lipid profile, blood pressure and estimated renal function.
Results: We did not find any long-term adverse effects of antenatal betamethasone, with the exception of an effect on glomerular filtration rate (GFR). In 19-year-old survivors, GFR was lower after betamethasone: –5.2 ml/min (95% CI –8.9 to –1.4) per 1.73 m2.
Conclusions: The reduction in neonatal mortality associated with a single course of maternal betamethasone is not accompanied by long-term metabolical risks in survivors of preterm birth. The only adverse effect found was lower GFR. Although this difference was not clinically relevant at 19 years, it might predict an increased risk of chronic renal failure in prematurely born individuals who were exposed antenatally to betamethasone.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
-
All Versions of this Article:
adc.2007.128470v1
93/6/F442 most recent - Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in ADC Online
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
